The Apellis Pharmaceuticals restructuring will save up to $300 million. It comes as the biotech continues its inquiry into the cause of a rare inflammatory complication reported in a small number of patients who received its geographic atrophy drug, Syfovre.

Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.

For the August episode, we discuss some recent executive appointments occurring in the healthcare sector, as well as layoffs affecting the industry. We also hear from Andrew Trister, who just became Verily’s chief scientific officer.

In this month’s episode, we dive into some recent executive appointments occurring in the healthcare world, as well as layoffs affecting the industry. We also hear from Leslie Orne, who recently became the new CEO of Trinity Life Sciences, which provides consulting services and technology solutions to life sciences firms looking to commercialize their product.

The restructuring of cardiovascular drugmaker Amarin means the layoff of about 30% of staff. Sales of Vascepa, the company’s only commercialized product, have suffered as generic versions gain traction in the market.

In this month’s episode, we dive into some of the recent executive appointments occurring in the healthcare sector, as well as layoffs affecting the industry. We also hear from Danny Sanchez, who recently became the new CEO of EmpiRx Health, a value-based pharmacy benefit manager.

Here is a selection of recent executive hires, exits, promotions and layoffs occurring across the healthcare industry.

In this month’s episode, we dive into some of the recent executive appointments occurring in the healthcare sector, as well as layoffs affecting the industry. We also hear from Lara Khouri, the new COO of Children’s Hospital Los Angeles, about her passion for pediatric healthcare.

Amazon recently announced that it is shuttering its Halo division, a line of wearable health and fitness devices. This marks the third time in about two years that the e-commerce giant has closed one its healthcare businesses — Amazon Care failed last year, and Haven failed in 2021.

Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.

In this month’s episode, we dive into some of the recent executive appointments occurring in the healthcare sector, as well as layoffs affecting the industry. We also hear from Dr. Rob Fields, who recently switched from his role as chief population health officer at Mount Sinai to chief clinical officer at Beth Israel Lahey Health.

Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.

In this month’s episode, we dive into some of the recent executive appointments occurring in the healthcare sector, as well as layoffs affecting the industry. We also hear from Tom Richards, who recently became the new executive vice president of business development at Transcarent after spending more than 35 years at Cigna.

MorphoSys’s emphasis on its clinical-stage cancer programs puts the spotlight on a myelofibrosis drug candidate from its 2021 acquisition of Constellation Pharmaceuticals. That small molecule could compete against drug candidates from GSK and Merck.

While Talaris Therapeutics is ending two clinical tests of its cell therapy in kidney transplant patients, a third study in the autoimmune condition scleroderma is continuing. Meanwhile, the biotech’s restructuring plan is pursuing “strategic alternatives” that could include a merger or sale.

Grifols said the layoffs sparked by its restructuring represent just 8% of its workforce. But the cuts will happen mainly in the Barcelona-based company’s U.S. plasma operations, source of most of the plasma that is the basis for its biologic medicines.

Here is a selection of recent executive hires, departures and layoffs occurring across the healthcare industry.

MedCity News is launching a new podcast called MedCity Moves focusing on healthcare’s corporate ladder. Published monthly, episodes will provide a summary of notable executive appointments and layoff news — as well as an interview with a recently-appointed healthcare leader or anyone that is experiencing a shift in their job.

Rubius Therapeutics was unable to secure financing to carry out its pivot to a new manufacturing process for its red blood cell-based cell therapies. The once high-flying biotech is now exploring options that could include a sale of the business or a merger with another company.

Kaleido Biosciences, formed by Flagship Pioneering as part of a wave of biotech companies developing microbiome therapies, has laid off its entire workforce and is winding down operations. The shutdown follows a strategic review that failed to turn up any deals to support its clinical-stage pipeline.

Regulatory setbacks for a new migraine treatment have led Zosano Pharma to restructure, laying off about 31% of its staff. Zosano is one of several biotechs that announced cost-saving measures this week.

Yumanity’s corporate restructuring means the biotech is now exploring “strategic alternatives” that could include a sale of the company or its assets. The biotech’s lead drug candidate is an experimental Parkinson’s disease drug currently in Phase 1 testing.

Deciphera Pharmaceuticals’ corporate restructuring will slash headcount by 35% and stop work on two drug programs. Going forward, the biotech said it will focus on developing drugs that have the potential to be the first or the best in their therapeutic classes.

A survey by MGMA revealed that 48% of medical practices have experienced furloughs, and 22% have experienced layoffs as a result of Covid-19. Those numbers are expected to increase in May if conditions continue for the next month.

The DNA testing company confirmed on Thursday that it would lay off about 100 employees. The restructuring was a result of slowing consumer demand.

A source familiar with the situation told MedCity that less than 4 percent of the company’s total corporate workforce across all offices was let go.

Spokesman Doug Shelton verified that IBM’s recent round of layoffs hit its Watson Health unit, but he did not specify how many individuals lost their jobs, according to The Herald Sun.

Counsyl’s layoffs are in sales support, marketing, design and engineering.